HCV Archives – Page 19 of 30 – Treatment Action Group

Gilead: Stop Blocking Access to Hepatitis C Treatment

May 5, 2015
Chad Cipiti

On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.

C U L8ter: Hepatitis C Eradication

April 8, 2015
Chad Cipiti

Hepatitis C is now curable. Now all we need is surveillance to monitor it, global funding to fight it, and targets set to address it By Tracy Swan The first global targets for eliminating hepatitis C virus (HCV) will be…

On Targets and Timelines

April 8, 2015
Chad Cipiti

By Tim Horn With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization…

TAGline Spring 2015

April 8, 2015
Chad Cipiti

On Targets and Timelines: With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.

Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries

February 2, 2015
Chad Cipiti

Liver disease from hepatitis C virus (HCV) is one of the leading causes of death around the world. At least 185 million people have been infected and almost 500,000 people die from it each year. The hope for eradicating HCV has recently gained new momentum: effective treatments reaching a 100 percent cure rate in clinical trials are now available.

2014 TAG Update

December 11, 2014
Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

A Drug by Any Other Name

September 30, 2014
Chad Cipiti

The basics of generic medications, bioequivalence, and the push for good manufacturing practices Tim Horn Securing access to generic drugs to treat HIV, hepatitis C virus (HCV), and tuberculosis (TB) is now one of the most prominent strategies of global…

TAGline Fall 2014

September 30, 2014
Chad Cipiti

Hello Generics: A Drug by Any Other Name; The Road to Treatment Access; Safeguarding Against Stockouts; Generics vs. the Giant

Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug

July 24, 2014
Chad Cipiti

Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s Executive Vice President of Corporate and Medical Affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.”

2014 Pipeline Report

July 18, 2014
Chad Cipiti

July 20, 2014 HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn…